In South San Francisco, Genentech showed that recombinant DNA technology could transform medicine and create therapies once ...

CNBC’s Jim Cramer delivers his daily Mad Dash.

Brandon Capital will receive more than $300 million from the sale of Myricx, which is developing cancer-killing “biological ...

As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.

Gareth Soloway's technical market breakdown: S&P 500 trend-line test, semiconductor unwind, AI-to-biotech rotation, USD/JPY ...

Parabilis Medicines, NewLimit, Enliven Therapeutics, and Kardigan bagged the biggest biotech funding rounds overall in June 2026.

VERAXA Biotech (NASDAQ: VRXA) provided a corporate and pipeline update highlighting progress during the first half of 2026, ...

As climate change brings longer droughts, more frequent heat waves and increasingly unpredictable growing conditions to ...

Novartis will pay $1.1bn upfront and up to $400m in milestones for Myricx Bio, a UK firm developing a novel payload for antibody-drug conjugates.

Novel conditionally active T cell engagers sourced from proprietary BiTAC® platform are at the basis of advanced partnering initiatives and development activitiesZURICH, SWITZERLAND – July 6, 2026 -- ...

ZURICH, July 6 (Reuters) - Swiss drugmaker Novartis said on Monday it had agreed to pay up to $1.5 billion for U.K.-based ...

A series of biotech acquisitions transpired in under 9 months — totaling more than $3.5 billion. The drugs behind them target ...